Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review
Background: Clozapine is the only Food and Drug Administration (FDA) and National Institute for Care and Excellence (NICE) approved drug for treatment-resistant schizophrenia (TRS). Its potentially life-threatening haematological side effects of neutropaenia and agranulocytosis mandate rigorous moni...
Glavni autori: | , |
---|---|
Format: | Članak |
Jezik: | English |
Izdano: |
AOSIS
2023-10-01
|
Serija: | South African Journal of Psychiatry |
Teme: | |
Online pristup: | https://sajp.org.za/index.php/sajp/article/view/2039 |